TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02315196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT03491904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab AI
Description: Self-administered with auto injector
Study: NCT02315196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT03491904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab PFS
Description: Prefilled syringe administered by study staff
Study: NCT02315196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00616772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Capsule
Study: NCT02295436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minodronic acid
Description: comparison of different doses, ages and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minodronic acid
Description: comparison of different doses, ages and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minodronic acid
Description: comparison of different doses, ages and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minodronic acid
Description: comparison of different doses, ages and medication conditions
Study: NCT01695213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uncemented total hip arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uncemented total hip arthroplasty
Study: NCT01782404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
Study: NCT05840523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation exercises
Description: The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
Study: NCT02909686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boswellia Serrata

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study: NCT05840523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Range Of Motion exercises
Description: The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
Study: NCT03862755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
Description: Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
Study: NCT02887456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment using Vitapex
Description: Endodontic treatment using Vitapex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endodontic treatment using MTA paste
Description: Endodontic treatment using MTA paste
Study: NCT01996618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
Study: NCT02373189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
Study: NCT02084602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Orally administration of artesunate 4mg/Kg by three days
Study: NCT00369278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Tablets for oral administration
Study: NCT03086148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
Study: NCT00446797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-selective NSAIDS
Description: Non-selective NSAIDs administered at usual (standard) doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
Study: NCT03632551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific binaural hearing evaluations
Description: Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific binaural hearing evaluations
Description: Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
Study: NCT02084602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
Study: NCT03632551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific binaural hearing evaluations
Description: Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
Study: NCT03547037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: JNJ-63723283 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: JNJ-63723283 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib will be administered orally.
Study: NCT03694327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-101-M
Description: Mobile Application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: Mobile Application
Study: NCT01160172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392103A
Description: intramuscular vaccination according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392105A
Description: intramuscular vaccination according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392106A
Description: intramuscular vaccination according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcal investigational vaccine GSK2392019A
Description: intramuscular vaccination according to protocol schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: intramuscular vaccination according to protocol schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: intramuscular vaccination according to protocol schedule
Study: NCT03808532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cura+ Moisturizing Cream
Description: Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
Study: NCT03384212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study: NCT02909686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epimedium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luteolin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nettle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pycnogenol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reishi Mushroom

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00398138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-1 analog peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study: NCT01234311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasquinimod
Description: Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02116738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap Transposition Procedures
Description: Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
Study: NCT03948594

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resource
Description: 1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plain water
Description: 250ml plain water
Study: NCT01877811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXDX-105
Description: During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
Study: NCT04741295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
Study: NCT04506281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant treatment
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Study: NCT02321397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Prolonged Release Tablets
Study: NCT02061904

Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA: dual energy X-ray absorptiometry
Description: Bone mineral density development measured with dual energy X-ray absorptiometry

Intervention type: OTHER
Group type: OTHER
Intervention: Short Form Health Survey 12
Description: questionnaire for general health monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: VAS-satisfaction
Description: questionnaire for intervention satisfaction monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: VAS-pain
Description: questionnaire for pain monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Harris Hip Score
Description: questionnaire for hip function monitoring
Study: NCT00880100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrase® MT12
Description: Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
Study: NCT04104841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally Enhancing Adolescents' Mood in Schools
Description: 8-session modified behavioral activation intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Referral to school mental health provider, social worker, or community care.
Study: NCT03929406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Tissue Imprint
Description: Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal.
Study: NCT03021590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500Mg Oral Tablet
Description: Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500Mg Oral Tablet
Description: Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
Study: NCT03275116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 'Respimat' 5 mcg
Description: Once daily single bronchodilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium Bromide/Formoterol Fumarate 340/12 mcg
Description: Twice daily dual bronchodilation
Study: NCT03468075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered on Days 1, 8 and 15, after the infusion of ascorbate
Study: NCT04697836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST
Description: After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST
Description: After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients.
Study: NCT03210714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT00085358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given intraperitoneally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV or intraperitoneally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT02690389

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Flumazenil
Description: used alone or with acupuncture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: used alone or with acupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: used alone or with flumazenil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: used alone or with flumazenil
Study: NCT03907592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Description: Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Description: Supplementation of 4000 mg L-leucine per day throughout the study period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training at the gym, twice a week for 24 weeks (48 training units in total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training at the gym, twice a week for 24 weeks (48 training units in total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
Study: NCT05423704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
Study: NCT02005510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed in-home high-risk HPV testing kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study: NCT04151446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Scleral Microporation
Description: Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.